Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
Lonza announced the launch of its new Design2Optimize™ platform to enhance process development and manufacturing of small molecule APIs.
read more
Wednesday, October 07, 2020
Lonza Bioscience has announced the commercial release of the PyroCell™ MAT System, a sustainable and reliable solution for in vitro pyrogen testing.
read more
Lonza is opening a dedicated cell-and-gene-therapy facility, which was built in anticipation of the rising demand from developers of cell and gene therapies.
read more
Monday, November 19, 2018
Lonza Pharma & Biotech has opened its Collaborative Innovation Center (CIC) in the Haifa Life Science Park, Israel.
read more
Monday, November 07, 2016
Lonza has opened its pharmaceutical Drug Product Services laboratories in the Stücki Science Park Basel (CH). Scientists in the new 1300 m2 facility will focus initially on formulation development, drug product analytical development and quality ...
read more
Tuesday, November 29, 2022
Lonza and AbTis, a Korean biotechnology company announced that the companies are collaborating to advance the precision of bioconjugation strategies for novel bioconjugates-based therapies.
read more
Lonza and Vineti announced a partnership in the cell and gene therapy field and across Lonza's 'vein-to-vein' delivery network.
read more
Wednesday, October 08, 2025
Lonza announced the operational readiness of its new aseptic drug product filling line in Stein, Switzerland. The filling line was granted a GMP license following Swissmedic approval, strengthening Lonza’s existing capacity for liquid and lyophilized...
read more
Jaggaer announced that Lonza is using Jaggaer’s Sourcing Director solution to automate and streamline their sourcing process.
read more
Lonza has selected Rockwell Automation for the turnkey implementation of the Lonza strategic vision of bringing the digital factory to nine former Capsugel facilities that manufacture drug capsules.
read more
Synpromics announce a partnership for the commercialization of a number of inducible promoters to improve the manufacturing of biopharmaceuticals.
read more
Lonza announced its entry into a binding contractual commitment for the purchase of a sterile drug product fill & finish facility from Novartis.
read more
Lonza announced it has acquired Synaffix B.V. (Synaffix), a biotechnology company focused on commercializing its clinical-stage technology platform for the development of ADCs.
read more
Following the recent FDA approval of the PAS for second-generation Andexxa, Portola and Lonza announce the start of supply of the recombinant coagulation factor from Lonza’s Porriño facility.
read more
Lonza has entered into a definitive agreement to divest its Capsules & Health Ingredients (CHI) business to Lone Star Funds for an enterprise value of CHF 2.3 billion (USD 3 billion). Lonza will realize upfront cash proceeds of CHF 1.7 billion (USD 2...
read more